NCT00799877

Inclusion Criteria:

1. An adult patient (18 years of age or older) with chronic plaque psoriasis who has been
prescribed HUMIRA® therapy according to the local product labeling and meets one of
the following criteria:

- New initiated (within 4 weeks of registry entry) on HUMIRA® therapy;

- Initiated HUMIRA® therapy in the past and:

- Has received continuous (no more than 70 consecutive days off drug) HUMIRA®
therapy and the physician can provide source documentation of SAEs, AEs, of
Special Interest, and dosing information since initiation of therapy.

OR

- Is entering after participation in an AbbVie HUMIRA (adalimumab) sponsored study
and has received continuous (no more than 70 consecutive days off drug) HUMIRA®
therapy after the completion of AbbVie sponsored study and physician can provide
source documentation of SAEs, AEs of Special Interest, and dosing information
since initiation of commercial HUMIRA® (defined as a prescribed/non study drug).

2. Patient is willing to consent to data being collected and provided to AbbVie;

3. Patient is capable of and willing to give written informed consent and to comply with
the requirements of the registry.

Exclusion Criteria:

- Patient should not be enrolled if he/she cannot be treated in accordance with the local
product label.